Benzonatate: Nursing Drug Guide, Swallow-Whole Safety & Pediatric Overdose

Benzonatate is supplied as oral softgel or liquid-filled capsules, commonly 100 mg and 200 mg strengths. Always verify strength and capsule type on the MAR—patients may confuse antitussives with other cough products at home.

Common brand names include Tessalon, Tessalon Perles, and Zonatuss. Overlapping home products such as guaifenesin (expectorant) or sedating antihistamine cough syrups (e.g., diphenhydramine) do not replace benzonatate safety teaching—duplicate antitussive therapy and sedation stacking still require medication reconciliation.

Benzonatate is a non-narcotic antitussive used for symptomatic relief of cough when nonpharmacologic measures and underlying cause treatment are insufficient. Nurses most often see it ordered for irritative cough associated with upper respiratory infections such as the common cold or bronchitis. It suppresses the cough reflex—it does not treat infection, bronchospasm, or retained secretions.

↔On a small screen, swipe or scroll sideways to see the full table.

Benzonatate is chemically related to para-aminobenzoic acid (PABA) ester local anesthetics such as procaine and tetracaine. It acts peripherally by anesthetizing the stretch receptors in the respiratory passages, lungs, and pleura—reducing the cough reflex at its source. When the capsule integrity is broken in the mouth, the same local anesthetic effect occurs in the oropharynx, which is why chewing or crushing is dangerous rather than merely “less effective.”

Dosing per FDA DailyMed prescribing information for benzonatate capsules. Always verify the prescriber order, patient age, and 24-hour total before administration.

Missed dose: Not specified in the reviewed prescribing information. For PRN antitussive use, give only if cough recurs and the minimum interval since the last dose has passed without exceeding the daily maximum.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Confirm patient age is greater than 10 years unless prescriber and pharmacy have documented an exceptional plan—labeling states use under 10 is not established
• Verify ability to swallow capsules whole; assess dysphagia, developmental stage in adolescents, and prior chew/crush errors with medications
• Review allergy history—including ester local anesthetic or PABA-class sensitivity—and reconcile home cough/cold products on admission
• Calculate total benzonatate milligrams in the last 24 hours; confirm no duplicate antitussive orders (including promethazine combinations)

Contraindications

• Known hypersensitivity to benzonatate or related compounds
• Do not administer if the patient cannot reliably swallow the capsule whole without chewing

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral capsules only. Per labeling, capsules should be swallowed whole—do not break, chew, cut, crush, or dissolve in the mouth.

• Give with a full glass of water; observe the patient swallow the intact capsule when feasible (especially first dose in children over 10 and anyone with swallowing difficulty)
• Do not open capsules for enteral tube administration unless pharmacy provides an explicit alternative—opening destroys the swallow-whole safety design
• Apply the same verification rigor as other high-consequence oral meds: follow medication administration rights and high-alert medication administration double-check steps when institutional policy lists benzonatate or pediatric antitussives as high risk

• Decrease in cough frequency or intensity within approximately 15–20 minutes when the capsule was swallowed intact
• Patient remains alert with normal speech and swallowing—oral numbness is not an expected therapeutic effect
• No worsening respiratory distress; if cough persists with fever, hypoxia, or increased work of breathing, reassess underlying cause rather than repeating doses to maximum

Overdose manifestations may occur within 15–20 minutes and progress rapidly—especially in children. Hold further doses and escalate immediately.

• Numbness or tingling of the mouth, tongue, or throat after dose (may indicate chew/crush release or early toxicity)
• Choking sensation, drooling, hoarse voice, or inability to swallow—airway compromise from oropharyngeal anesthesia
• Confusion, restlessness, tremor, seizures, or loss of consciousness
• Hypotension, cardiac arrhythmias, or cardiac arrest per overdose labeling
• Known or suspected ingestion above maximum daily dose, access to additional capsules by a child, or caregiver report that the capsule was chewed
• Hypersensitivity: bronchospasm, laryngospasm, cardiovascular collapse, or anaphylactoid reaction

↔On a small screen, swipe or scroll sideways to see the full table.

Structured frequency data for individual adverse events are not specified in the reviewed prescribing information.

Overdose may occur when too many capsules are ingested—or when capsules are chewed, crushed, or cut, releasing a toxic amount of local anesthetic. Signs and symptoms may appear within 15–20 minutes and progress rapidly to restlessness, tremors, seizures, coma, and cardiac arrest. Pediatric fatalities have occurred after exploratory chewing. There is no specific antidote listed in prescribing information.

Early signs

• Restlessness, tremor, convulsions, coma
• Oral and pharyngeal numbness with choking symptoms after administration error
• Cardiovascular collapse and cardiac arrest in severe toxicity

Management (nursing priorities)

Activate emergency response and contact local poison control or medical toxicology per facility protocol. Supportive care includes airway management, oxygen, IV fluids, and seizure control. Labeling states: administer activated charcoal; avoid CNS stimulants; IV barbiturate may be used for seizures if they occur. Continue monitoring until toxicology guidance indicates stability.

• Benzonatate vs benztropine (Cogentin)—sound-alike names; antitussive vs anticholinergic—verify active ingredient on MAR
• Benzonatate vs benzocaine / local anesthetic products—same ester-anesthetic class; allergy cross-reactivity possible
• Softgel capsules vs candy—pediatric and cognitively impaired adults may mouth or chew round liquid-filled capsules; store securely out of reach
• 100 mg vs 200 mg capsules—double-strength error approaches daily maximum with one extra dose
• Tessalon Perles vs other “perle” softgels—confirm drug name, not just capsule appearance
• Duplicate cough therapy—benzonatate plus sedating antihistamine or opioid antitussive without prescriber intent

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Cough frequency and effect on rest or sleep after intact swallow—onset expected within about 15–20 minutes
• Oral numbness, choking, drooling, speech changes, mental status, tremor, and respiratory effort after each dose—especially first dose in pediatric patients
• Vital signs and neurologic status if overdose or chew/crush exposure suspected; continuous monitoring per emergency protocol

Document

• Dose, strength (100 vs 200 mg), time, route, and running 24-hour total (maximum 600 mg/day)
• Swallow-whole teaching provided and caregiver verbalization when applicable
• Any numbness, choking, neurologic changes, or emergency escalation—including poison control/toxicology consultation

• Swallow the capsule whole with water—do not chew, crush, cut, or dissolve it in your mouth. Chewing can numb the throat and cause choking or serious overdose
• Do not exceed the prescribed number of capsules in 24 hours (maximum 600 mg/day for adults and children over 10 per labeling)
• Keep capsules out of reach of young children—even one chewed capsule can be life-threatening
• Seek emergency care immediately for mouth numbness, choking, confusion, shakiness, seizures, or if a child may have chewed a capsule—contact local poison control or toxicology per facility guidance
• This medicine treats cough symptoms only; return for worsening breathing difficulty, high fever, or cough lasting more than one week per labeling patient guidance

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for benzonatate using a tabbed outpatient case (MAR, vitals, history, nursing notes), then work through priority action, cue recognition, trend interpretation after a chew error, documentation cloze, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.